Hydrophilically enhanced 3-carboranyl thymidine analogues (3CTAs) for boron neutron capture therapy (BNCT) of cancer

Sureshbabu Narayanasamy, B. T.S. Thirumamagal, Jayaseharan Johnsamuel, Youngjoo Byun, Ashraf Al Madhoun, Elena Usova, Guirec Y. Cosquer, Junhua Yan, Achintya K. Bandyopadhyaya, Rohit Tiwari, Staffan Eriksson, Werner Tjarks

Research output: Contribution to journalArticlepeer-review

25 Citations (Scopus)


Five novel 3-carboranyl thymidine analogues (3CTAs) were designed and synthesized for boron neutron capture therapy (BNCT) of cancer. Phosphorylation of all five 3CTAs was catalyzed by recombinant human thymidine kinase (hTK1) using adenosine triphosphate (ATP) as the phosphate donor. The obtained phosphorylation rates ranged from 4% to 64.5% relative to that of thymidine. The compound with the most favorable hTK1 binding properties had a kcat/KM value of 57.4% relative to that of thymidine and an IC50 of inhibition of thymidine phosphorylation by hTK1 of 92 μM. Among the five synthesized 3CTAs, this agent had also the overall most favorable physicochemical properties. Therefore, it may have the potential to replace N5-2OH, the current lead 3CTA, in preclinical studies. An in silico model for the binding of this compound to hTK1 was developed.

Original languageEnglish
Pages (from-to)6886-6899
Number of pages14
JournalBioorganic and Medicinal Chemistry
Issue number20
Publication statusPublished - 15 Oct 2006


  • 3-Carboranyl thymidine analogues (3CTAs)
  • Boron neutron capture therapy (BNCT)
  • Thymidine kinase 1 (TK1)


Dive into the research topics of 'Hydrophilically enhanced 3-carboranyl thymidine analogues (3CTAs) for boron neutron capture therapy (BNCT) of cancer'. Together they form a unique fingerprint.

Cite this